Neuro-Oncology · 2023 · 15 citations · 33 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyImmunotherapy For Brain TumorsImmunotherapy For Solid TumorsT Cell Responses To TumorsTumor-associated AntigensAntigen-specific T Cell ResponsesCytotoxicity AssaysGlioblastoma ImmunotherapyPeptide VaccinationT Cell CytotoxicityT Cell Receptor SequencingT Cell-based ImmunotherapyTherapeutic Vaccine Efficacy
BACKGROUND: Neuroligin 4 X-linked (NLGN4X) harbors a human leukocyte antigen (HLA)-A*02-restricted tumor-associated antigen, overexpressed in human gliomas, that was found to induce specific cytotoxic T cell responses following multi-peptide vaccination in patients with newly diagnosed glioblastoma. METHODS: T cell receptor (TCR) discovery was performed using droplet-based single-cell TCR sequencing of NLGN4X-tetramer-sorted T cells postvaccination. The identified TCR was delivered to Jurkat T cells and primary human T cells (NLGN4X-TCR-T). Functional profiling of NLGN4X-TCR-T was performed by flow cytometry and cytotoxicity assays. Therapeutic efficacy of intracerebroventricular NLGN4X-TCR-T was assessed in NOD scid gamma (NSG) major histocompatibility complex (MHC) I/II knockout (KO) (NSG MHC I/II KO) mice bearing NLGN4X-expressing experimental gliomas. RESULTS: An HLA-A*02-restricted vaccine-induced T cell receptor specifically binding NLGN4X131-139 was applied for preclinical therapeutic use. Reactivity, cytotoxicity, and polyfunctionality of this NLGN4X-specific TCR are demonstrated in various cellular models. Intracerebroventricular administration of NLGN4X-TCR-T prolongs survival and leads to an objective response rate of 44.4% in experimental glioma-bearing NSG MHC I/II KO mice compared to 0.0% in control groups. CONCLUSION: NLGN4X-TCR-T demonstrate efficacy in a preclinical glioblastoma model. On a global scale, we provide the first evidence for the therapeutic retrieval of vaccine-induced human TCRs for the off-the-shelf treatment of glioblastoma patients.Keywords cell therapy | glioblastoma | T cell receptor | tumor antigen.
33
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Richard A. Morgan, Mark E. Dudley, John R. Wunderlich et al. · Science · 2006 · 2.6K citations · Full text
Medicine, Immunology, Oncology +14
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown, Darya Alizadeh, Renate Starr et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text
Medicine, Immunology, Oncology +17
Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai et al. · Science Translational Medicine · 2017 · 1.8K citations · Full text
Medicine, Immunology, Oncology +17